Market Spotlight: Cervical Cancer
Market Spotlight: Cervical Cancer
$1,318.00
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Cervical Cancer market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2020, there were 610,200 incident cases of cervical cancer in females worldwide, and expects that number to increase to 665,600 incident cases by 2029.
- Approved drugs for cervical cancer target vascular endothelial growth factor, topoisomerase I, programmed death-1 receptor (PD-1)/programmed death ligands (PD-L1 and PD-L2), the immune system, reactive oxygen species/free radicals, and tissue factor. The majority of these therapies are administered via the intravenous route.
- The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with one drug in the NDA/BLA stage.
- Therapies in development for cervical cancer focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral, subcutaneous, intramuscular, intravesical, and intranasal formulations.
- High-impact upcoming events for drugs in the cervical cancer space comprise topline Phase I/II trial results for tiragolumab, topline Phase II trial results for bintrafusp alfa, topline Phase III trial results for Imfinzi, and an expected PDUFA date for biosimilar bevacizumab (Mylan/Biocon).
- The overall likelihood of approval of a Phase I solid tumors asset is 5.4%, and the average probability a drug advances from Phase III is 42.1%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.7 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for cervical cancer have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
- The US has a substantial lead in the number of cervical cancer clinical trials globally. Spain leads the major European markets, while China has the top spot in Asia.
- Roche has the highest number of completed clinical trials for cervical cancer, with 18 trials. AstraZeneca leads the industry sponsors with the highest overall number of clinical trials for cervical cancer, followed closely by Merck & Co.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiotherapy
9 Chemotherapy
10 Targeted therapy
10 Immunotherapy
11 EPIDEMIOLOGY
14 MARKETED DRUGS
17 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Libtayo for Cervical Cancer (January 28, 2022)
25 Balstilimab for Cervical Cancer (October 22, 2021)
25 Tivdak for Cervical Cancer (September 19, 2021)
27 Keytruda for Cervical Cancer (September 18, 2021)
29 Keytruda for Cervical Cancer (June 22, 2021)
31 Libtayo for Cervical Cancer (May 12, 2021)
32 Libtayo for Cervical Cancer (March 15, 2021)
34 Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
36 Balstilimab for Cervical Cancer (September 18, 2020)
39 KEY UPCOMING EVENTS
40 KEY REGULATORY EVENTS
40 Libtayo’s Last-Minute Withdrawal
40 China’s NMPA Accepts Lee’s NDA For Socazolimab
40 Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal
40 Keytruda Cements Cervical Cancer Leadership With First-Line Nod
41 Seagen/Genmab’s Tivdak Set To Take On Merck’s Keytruda
41 Agenus May Get Holiday Cheer
42 PROBABILITY OF SUCCESS
43 LICENSING AND ASSET ACQUISITION DEALS
43 GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
44 REVENUE OPPORTUNITY
46 CLINICAL TRIAL LANDSCAPE
47 Sponsors by status
48 Sponsors by phase
49 Recent events
52 BIBLIOGRAPHY
53 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of cervical cancer, 2020–29
17 Figure 2: Overview of pipeline drugs for cervical cancer in the US
17 Figure 3: Pipeline drugs for cervical cancer, by company
18 Figure 4: Pipeline drugs for cervical cancer, by drug type
18 Figure 5: Pipeline drugs for cervical cancer, by classification
27 Figure 6: Tivdak for Cervical Cancer (September 19, 2021): Phase I/II – innovaTV 205
29 Figure 7: Keytruda for Cervical Cancer (September 18, 2021): Phase III – KEYNOTE-826 (w/Chemotherapy, 1L)
31 Figure 8: Keytruda for Cervical Cancer (June 22, 2021): Phase III – KEYNOTE-826 (w/Chemotherapy, 1L)
32 Figure 9: Libtayo for Cervical Cancer (May 12, 2021): Phase III – vs. Chemotherapy
34 Figure 10: Libtayo for Cervical Cancer (March 15, 2021): Phase III – vs. Chemotherapy
36 Figure 11: Tisotumab Vedotin for Cervical Cancer (September 21, 2020): Phase II – innovaTV 204
38 Figure 12: Balstilimab for Cervical Cancer (September 18, 2020): Phase II – RaPiDS (+/- AGEN1884, 2nd Line)
39 Figure 13: Key upcoming events in cervical cancer
42 Figure 14: Probability of success in the solid tumors pipeline
46 Figure 15: Clinical trials in cervical cancer
46 Figure 16: Top 10 drugs for clinical trials in cervical cancer
47 Figure 17: Top 10 companies for clinical trials in cervical cancer
47 Figure 18: Trial locations in cervical cancer
48 Figure 19: Cervical cancer trials status
49 Figure 20: Cervical cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of cervical cancer, 2020–29
15 Table 2: Marketed drugs for cervical cancer
19 Table 3: Pipeline drugs for cervical cancer in the US
24 Table 4: Libtayo for Cervical Cancer (January 28, 2022)
25 Table 5: Balstilimab for Cervical Cancer (October 22, 2021)
26 Table 6: Tivdak for Cervical Cancer (September 19, 2021)
28 Table 7: Keytruda for Cervical Cancer (September 18, 2021)
30 Table 8: Keytruda for Cervical Cancer (June 22, 2021)
31 Table 9: Libtayo for Cervical Cancer (May 12, 2021)
33 Table 10: Libtayo for Cervical Cancer (March 15, 2021)
35 Table 11: Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
37 Table 12: Balstilimab for Cervical Cancer (September 18, 2020)
44 Table 13: Historical global sales, by drug ($m), 2016–20
45 Table 14: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Arthroscopy Products and Sports Medicine Fixation Implants (2021) 
Sign up to the